Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/22/2025

Follow-Up for Factor V Leiden

Clinical Surveillance Strategy

  • The American College of Medical Genetics recommends counseling about thrombosis risk factors, including oral contraceptive use, pregnancy, prolonged immobilization, surgery, and smoking, for patients with Factor V Leiden 1
  • The American College of Medical Genetics suggests providing thromboprophylaxis during high-risk periods, such as surgery, trauma, prolonged immobilization, or postpartum period, rather than continuous anticoagulation, for patients with Factor V Leiden 2
  • Pregnancy management planning is recommended for female carriers of Factor V Leiden, as knowledge of Factor V Leiden status influences peripartum thromboprophylaxis decisions, according to the American College of Medical Genetics 1

Management of Prior VTE

  • Heterozygous carriers with a single VTE episode typically receive standard duration anticoagulation (3-6 months) similar to non-carriers, as heterozygosity alone does not significantly increase recurrence risk, according to the American College of Medical Genetics 4
  • Homozygous carriers should be considered for lifetime anticoagulation after any thrombotic event due to substantially elevated recurrence risk, as recommended by the American College of Medical Genetics 2

Additional Thrombophilia Testing

  • Comprehensive thrombophilia evaluation, including testing for prothrombin 20210A mutation, is recommended at initial diagnosis rather than during follow-up, according to the American College of Medical Genetics 1
  • Measuring plasma homocysteine levels is recommended in Factor V Leiden-positive patients, as suggested by the American College of Medical Genetics 1

Family Screening Considerations

  • Selective family screening, including testing first-degree relatives of symptomatic probands, is recommended, as the annual VTE incidence is 0.45-0.67% if carriers versus 0.10% if non-carriers, according to the American College of Medical Genetics 1
  • Knowledge of carrier status in relatives guides decisions about oral contraceptive use, pregnancy management, and thromboprophylaxis during high-risk periods, as recommended by the American College of Medical Genetics 1